Year: 2021

A new drug increases the life expectancy of patients with very aggressive intraocular cancer

The results of a clinical trial, published in the New England Journal of Medicine, show that Tebentafusp is the first drug to increase overall survival in metastatic uveal melanoma, highly aggressive cancer that causes death in 50% of cases in less than a year.

IDIBELL receives a grant from the Generalitat to promote Personalized Medicine on campus

The Generalitat of Catalonia has awarded IDIBELL a co-financed project of 2 million euros that will consolidate Personalized Medicine on the Bellvitge campus. The money will be used to create and improve infrastructures that allow the management and storage of patient samples and derived data, ensuring their integrity and traceability.

Scroll to Top